JP4455321B2 - カルバメート置換ピラゾロピリジン類 - Google Patents

カルバメート置換ピラゾロピリジン類 Download PDF

Info

Publication number
JP4455321B2
JP4455321B2 JP2004503467A JP2004503467A JP4455321B2 JP 4455321 B2 JP4455321 B2 JP 4455321B2 JP 2004503467 A JP2004503467 A JP 2004503467A JP 2004503467 A JP2004503467 A JP 2004503467A JP 4455321 B2 JP4455321 B2 JP 4455321B2
Authority
JP
Japan
Prior art keywords
compound
formula
fluorobenzyl
pyrazolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004503467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531553A5 (OSRAM
JP2005531553A (ja
Inventor
クリスティナ・アロンソ−アリヤ
エルヴィン・ビショフ
クラウス・ミュンター
ヨハネス−ペーター・シュタッシュ
エルケ・シュタール
シュテファン・ヴァイガント
アヒム・フォイラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4455321(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2005531553A publication Critical patent/JP2005531553A/ja
Publication of JP2005531553A5 publication Critical patent/JP2005531553A5/ja
Application granted granted Critical
Publication of JP4455321B2 publication Critical patent/JP4455321B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2004503467A 2002-05-08 2003-04-25 カルバメート置換ピラゾロピリジン類 Expired - Lifetime JP4455321B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10220570A DE10220570A1 (de) 2002-05-08 2002-05-08 Carbamat-substituierte Pyrazolopyridine
PCT/EP2003/004304 WO2003095451A1 (de) 2002-05-08 2003-04-25 Carbamat-substituierte pyrazolopyridine

Publications (3)

Publication Number Publication Date
JP2005531553A JP2005531553A (ja) 2005-10-20
JP2005531553A5 JP2005531553A5 (OSRAM) 2009-12-10
JP4455321B2 true JP4455321B2 (ja) 2010-04-21

Family

ID=29265155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004503467A Expired - Lifetime JP4455321B2 (ja) 2002-05-08 2003-04-25 カルバメート置換ピラゾロピリジン類

Country Status (38)

Country Link
US (1) US7173037B2 (OSRAM)
EP (1) EP1506193B3 (OSRAM)
JP (1) JP4455321B2 (OSRAM)
KR (1) KR101011864B1 (OSRAM)
CN (1) CN1330649C (OSRAM)
AR (1) AR039789A1 (OSRAM)
AT (1) ATE330957T1 (OSRAM)
AU (1) AU2003233061B2 (OSRAM)
BE (1) BE2014C030I2 (OSRAM)
BR (1) BRPI0309855B8 (OSRAM)
CA (1) CA2485143C (OSRAM)
CU (1) CU23453B7 (OSRAM)
CY (2) CY1105579T1 (OSRAM)
DE (2) DE10220570A1 (OSRAM)
DK (1) DK1506193T3 (OSRAM)
DO (1) DOP2003000639A (OSRAM)
EC (1) ECSP045414A (OSRAM)
ES (1) ES2268363T3 (OSRAM)
FR (1) FR14C0032I2 (OSRAM)
GT (1) GT200300101A (OSRAM)
HR (1) HRP20041166B1 (OSRAM)
IL (1) IL164958A (OSRAM)
LU (1) LU92419I2 (OSRAM)
MX (1) MXPA04011003A (OSRAM)
MY (1) MY136841A (OSRAM)
NL (1) NL300659I2 (OSRAM)
NO (2) NO329105B1 (OSRAM)
NZ (1) NZ536417A (OSRAM)
PE (1) PE20040197A1 (OSRAM)
PL (1) PL214985B1 (OSRAM)
PT (1) PT1506193E (OSRAM)
RU (1) RU2339638C9 (OSRAM)
SI (1) SI1506193T1 (OSRAM)
TW (1) TWI282792B (OSRAM)
UA (1) UA78314C2 (OSRAM)
UY (1) UY27793A1 (OSRAM)
WO (1) WO2003095451A1 (OSRAM)
ZA (1) ZA200408925B (OSRAM)

Families Citing this family (328)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
AU2003291342A1 (en) * 2002-11-05 2004-06-07 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
US20070179155A1 (en) * 2003-06-20 2007-08-02 Brian Smith N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
EP1799210A1 (en) * 2004-10-05 2007-06-27 Bayer HealthCare AG A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction
WO2006071740A2 (en) 2004-12-23 2006-07-06 Arena Pharmaceuticals, Inc. 5ht2c receptor modulator compositions and methods of use
DE102005031575A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung
DE102005031576A1 (de) * 2005-07-06 2007-01-25 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Reperfusionsschäden
DE102005047945A1 (de) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102006044696A1 (de) * 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
DE102006054757A1 (de) * 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007015034A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
EP2144605A1 (en) * 2007-05-12 2010-01-20 Bayer HealthCare AG sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
DE102007026392A1 (de) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung
DE102008052013A1 (de) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102007061756A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
EP2288585A1 (en) * 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
DE102008018675A1 (de) 2008-04-14 2009-10-15 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
CN102026640A (zh) * 2008-05-10 2011-04-20 拜耳先灵制药股份公司 用于治疗听力损害的sGC刺激剂、sGC活化剂及其组合
US8791146B2 (en) * 2008-05-29 2014-07-29 Bayer Intellectual Property Gmbh 2-alkoxy-substituted dicyanopyridines and their use
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008054205A1 (de) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie
AU2009322836B2 (en) * 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
MA32967B1 (fr) * 2009-01-17 2012-01-02 Bayer Schering Pharma Ag Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009016553A1 (de) 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US9260424B2 (en) * 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
UY33040A (es) * 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
RS59908B1 (sr) 2009-11-27 2020-03-31 Adverio Pharma Gmbh Postupak za proizvodnju metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata
EP2513101A1 (de) 2009-12-14 2012-10-24 Bayer Intellectual Property GmbH Neue solvate von methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat
RS54336B1 (sr) * 2010-02-05 2016-02-29 Adverio Pharma Gmbh Sgc stimulatori ili sgc aktivatori, sami za sebe i kombinovani sa pde5 inhibitorima za tretman cistične fibroze
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
CA2791100C (en) 2010-02-27 2018-01-30 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
CN103097387B (zh) 2010-07-09 2016-11-02 拜耳知识产权有限责任公司 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
KR20130132392A (ko) 2010-07-09 2013-12-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 가용성 구아닐레이트 시클라제의 자극제로서의 고리-융합된 4-아미노피리미딘 및 그의 용도
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
DE102010031148A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Ag Annellierte 4-Aminopyrimidine und ihre Verwendung
DE102011007891A1 (de) 2011-04-21 2012-10-25 Bayer Pharma Aktiengesellschaft Annellierte 4-Aminopyrimidine und ihre Verwendung
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
DE102010031666A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Carbamat-substituierte Diaminopyrimidine und ihre Verwendung
DE102010031667A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung
DE102010031665A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung
EP2611433A2 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
WO2012030939A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
DE102011006974A1 (de) 2011-04-07 2012-10-11 Bayer Pharma Aktiengesellschaft Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung
ES2544532T3 (es) 2010-12-07 2015-09-01 Bayer Intellectual Property Gmbh Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
DE102010062544A1 (de) 2010-12-07 2012-06-14 Bayer Schering Pharma Aktiengesellschaft Substituierte 1-Benzylcycloalkylcarbonsäuren und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
DE102012200356A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
DE102011075399A1 (de) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
DE102012200357A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
DE102011007890A1 (de) 2011-04-21 2012-10-25 Bayer Pharma Aktiengesellschaft Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung
DE102011075398A1 (de) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
EA201391769A1 (ru) 2011-05-30 2014-04-30 Астеллас Фарма Инк. Имидазопиридиновые соединения
MX2014000031A (es) 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
AU2012280246A1 (en) * 2011-07-06 2014-01-23 Bayer Intellectual Property Gmbh Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
DE102012200354A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
DE102011078715A1 (de) 2011-07-06 2013-01-10 Bayer Pharma AG Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
MX2014000316A (es) 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
DE102012200351A1 (de) 2012-01-11 2013-07-11 Bayer Pharma Aktiengesellschaft Substituierte annellierte Pyrimidine und ihre Verwendung
DE102011082041A1 (de) 2011-09-02 2013-03-07 Bayer Pharma AG Substituierte annellierte Pyrimidine und ihre Verwendung
JP6054967B2 (ja) 2011-09-02 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アネレート化ピリミジンおよびその使用
EA030018B1 (ru) * 2011-11-25 2018-06-29 Адверио Фарма Гмбх Способ получения замещенного 5-фтор-1h-пиразолопиридина
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
EP2802584B1 (en) 2012-01-13 2015-11-18 Novartis AG Salts of an ip receptor agonist
ES2644781T3 (es) 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos sustituidos y su uso
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
JP6118965B2 (ja) 2012-04-16 2017-04-26 トーアエイヨー株式会社 ２環性化合物
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
SG10201700454PA (en) 2012-07-20 2017-03-30 Bayer Pharma AG Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
JP6324956B2 (ja) 2012-07-20 2018-05-16 バイエル・ファルマ・アクティエンゲゼルシャフト 置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用
JP2015534563A (ja) 2012-10-09 2015-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 体重管理の方法
JP6056872B2 (ja) 2012-11-30 2017-01-11 アステラス製薬株式会社 イミダゾピリジン化合物
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
HK1217488A1 (zh) * 2013-02-21 2017-01-13 Adverio Pharma Gmbh {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
KR20150121007A (ko) 2013-03-01 2015-10-28 바이엘 파마 악티엔게젤샤프트 트리플루오르메틸-치환된 고리-융합된 피리미딘 및 그의 용도
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014131741A1 (de) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Benzyl-substituierte pyrazolopyridine und ihre verwendung
RS59981B1 (sr) 2013-03-15 2020-03-31 Cyclerion Therapeutics Inc Sgc stimulatori
CA2914040A1 (en) * 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
ES2625744T3 (es) 2013-06-04 2017-07-20 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso
EP3019506A1 (de) 2013-07-10 2016-05-18 Bayer Pharma Aktiengesellschaft Benzyl-1h-pyrazolo[3,4-b]pyridine und ihre verwendung
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
WO2015018814A1 (de) * 2013-08-08 2015-02-12 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung
US20160221965A1 (en) 2013-09-16 2016-08-04 Bayer Pharma Aktiengesellschaft Disubstituted trifluoromethyl pyrimidinones and their use
ES2659043T3 (es) 2013-10-07 2018-03-13 Bayer Pharma Aktiengesellschaft Tienouracil-carboxamidas cíclicas y su uso
WO2015056663A1 (ja) 2013-10-15 2015-04-23 トーアエイヨー株式会社 ４－アミノメチル安息香酸誘導体
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
WO2015063287A1 (en) 2013-11-01 2015-05-07 Bergen Teknologioverføring As Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
HK1224288A1 (zh) 2013-11-08 2017-08-18 Bayer Pharma Aktiengesellschaft 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CA2929753A1 (en) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils and use thereof
EP3079701B1 (en) 2013-12-11 2021-08-11 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20160311826A1 (en) * 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
AU2014364735A1 (en) 2013-12-19 2016-07-07 Bayer Pharma Aktiengesellschaft Substituted piperidinyl-tetrahydroquinolines
CN106029648A (zh) 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
CA2934134A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
CA2939793A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
EP3126358A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
CA2944617A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CN116655627A (zh) 2014-08-01 2023-08-29 拜耳医药股份有限公司 一种化合物的制备方法及其纯化以用作活性药物成分
US20170233413A1 (en) 2014-08-29 2017-08-17 Bayer Pharma Aktiengesellschaft Substituted annulated pyrimidines and use thereof
CN107074883A (zh) 2014-08-29 2017-08-18 拜耳医药股份有限公司 氨基取代的环状嘧啶及其用途
WO2016037954A1 (de) 2014-09-09 2016-03-17 Bayer Pharma Aktiengesellschaft Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung
AU2015317824A1 (en) 2014-09-17 2017-03-23 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sGC stimulators
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
SG11201703199UA (en) 2014-11-03 2017-05-30 Bayer Pharma AG Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
CN104374861B (zh) * 2014-11-10 2016-03-02 广东东阳光药业有限公司 一种用hplc分离测定利奥西呱原料药的有关物质的方法
CN104434845B (zh) * 2014-11-12 2017-12-05 广东东阳光药业有限公司 一种包含利奥西呱的固体药物制剂
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP3227287B1 (de) 2014-12-02 2019-08-07 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
CN105777743A (zh) * 2014-12-19 2016-07-20 奥浦顿（上海）医药科技有限公司 一种吡唑并[3,4-b]吡啶类化合物中间体的制备方法和应用
CN104530044B (zh) * 2014-12-31 2016-07-13 安徽联创生物医药股份有限公司 一种利奥西呱的合成方法
WO2016113205A1 (de) 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Substituierte pentafluorethylpyrimidinone und ihre verwendung
WO2016113415A1 (en) 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
BR112017023855A2 (pt) 2015-05-06 2018-07-17 Bayer Pharma Aktiengesellschaft o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc)
US10245264B2 (en) 2015-05-27 2019-04-02 Merck Sharp & Dohme Corp. Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
WO2016191335A1 (en) 2015-05-28 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
ES2839248T5 (es) 2015-07-23 2024-02-22 Bayer Pharma AG Estimuladores y/o activadores de la guanilatociclasa soluble (sGC) en combinación con un inhibidor de la endopeptidasa neutra (inhibidor de NEP) y/o un antagonista de angiotensina AII y su uso
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
LT3337800T (lt) 2015-08-21 2019-08-12 Bayer Pharma Aktiengesellschaft (4s)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamido, skirto naudoti kaip veikliojo farmacinio ingrediento, gamybos būdas ir gryninimas
EP3373936A1 (en) 2015-11-13 2018-09-19 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
JP2018538296A (ja) 2015-12-10 2018-12-27 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
EA201891374A1 (ru) 2015-12-10 2018-11-30 Байер Фарма Акциенгезельшафт Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
WO2017106175A2 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
US10414766B2 (en) * 2015-12-15 2019-09-17 Alembic Pharmaceuticals Limited Polymorph of Riociguat and its process for the preparation
CN105461715B (zh) * 2015-12-15 2017-03-29 郑州大明药物科技有限公司 一种利奥西呱中间体的合成方法
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
AR108265A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Derivados de feniltriazol sustituidos con amida y usos de estos
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
EP3452457B1 (en) 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US10526314B2 (en) 2016-05-03 2020-01-07 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017200857A1 (en) 2016-05-18 2017-11-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｓｇｃ刺激剤の固体形態
KR102513343B1 (ko) 2016-07-07 2023-03-22 사이클리온 테라퓨틱스, 인크. sGC 자극제의 인 전구약물
WO2018011017A1 (de) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190005A1 (ar) * 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
EP3296298A1 (de) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN109963858A (zh) 2016-09-23 2019-07-02 拜耳股份公司 N3－环状取代的噻吩并尿嘧啶及其用途
CN110022871A (zh) * 2016-10-11 2019-07-16 拜耳制药股份公司 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
CN107964011A (zh) * 2016-10-19 2018-04-27 中国人民解放军军事医学科学院毒物药物研究所 取代吡唑并吡啶类衍生物及其医药用途
US10927098B2 (en) 2016-10-20 2021-02-23 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
WO2018089328A1 (en) 2016-11-08 2018-05-17 Ironwood Pharmaceuticals, Inc. Treatment of cns diseases with sgc stimulators
WO2018089330A2 (en) 2016-11-08 2018-05-17 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3554488A2 (en) 2016-12-13 2019-10-23 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EA202192558A1 (ru) * 2016-12-14 2021-12-07 Байер Акциенгезельшафт Замещенные диазагетеробициклические соединения и их применение
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
EP3338764A1 (de) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
EP3338803A1 (de) 2016-12-21 2018-06-27 Bayer Pharma Aktiengesellschaft Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
WO2018130226A1 (zh) * 2017-01-16 2018-07-19 苏州科睿思制药有限公司 利奥西呱的新晶型及其制备方法和用途
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
EP3609869A1 (de) 2017-04-10 2020-02-19 Bayer Aktiengesellschaft Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
ES2924359T3 (es) 2017-04-11 2022-10-06 Sunshine Lake Pharma Co Ltd Compuestos de indazol sustituidos con flúor y usos de los mismos
CN108690016B (zh) * 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
US11230540B2 (en) 2017-10-24 2022-01-25 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
SG11202003049WA (en) 2017-10-24 2020-04-29 Bayer Ag Prodrugs of substituted triazole derivatives and uses thereof
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
CN111225917A (zh) 2017-10-24 2020-06-02 拜耳股份公司 取代咪唑并吡啶酰胺及其用途
US11337973B2 (en) 2017-11-07 2022-05-24 Bayer Aktiengesellschaft Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors
KR20200094762A (ko) 2017-12-01 2020-08-07 바이엘 파마 악티엔게젤샤프트 제약 성분으로서 사용하기 위한 (3s)-3-(4-클로르-3-｛[(2s,3r)-2-(4-클로르페닐)-4,4,4-트리플루오르-3-메틸부타노일]아미노}페닐)-3-시클로-프로필프로판산 및 그의 결정질 형태를 제조하는 방법
EA202091502A1 (ru) * 2017-12-19 2020-11-12 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
PE20210124A1 (es) 2018-03-07 2021-01-19 Cyclerion Therapeutics Inc FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC)
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
CA3100221A1 (en) 2018-05-17 2019-11-21 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
JP7457658B2 (ja) 2018-05-22 2024-03-28 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 フェニル置換ジヒドロナフチリジン化合物及びその使用
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
MX2021000363A (es) 2018-07-11 2021-04-29 Cyclerion Therapeutics Inc Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
EP3826619A1 (de) 2018-07-24 2021-06-02 Bayer Aktiengesellschaft Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
BR112020026644A2 (pt) 2018-07-24 2021-03-23 Bayer Aktiengesellschaft Forma de dosagem farmacêutica que pode ser administrada oralmente e tem liberação modificada
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
PE20211285A1 (es) 2018-11-27 2021-07-19 Bayer Ag Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
WO2020165031A1 (de) 2019-02-15 2020-08-20 Bayer Aktiengesellschaft Substituierte isochinolin-piperidinylmethanon-derivate
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
SG11202111587VA (en) 2019-05-07 2021-11-29 Bayer Ag Masp inhibitory compounds and uses thereof
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途
TWI867088B (zh) 2019-11-06 2024-12-21 德商拜耳廠股份有限公司 經取代之雜環甲醯胺及其用途
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
WO2021167458A1 (en) 2020-02-21 2021-08-26 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
US20230083417A1 (en) 2020-02-26 2023-03-16 Universiteit Maastricht Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
WO2021195403A1 (en) 2020-03-26 2021-09-30 Cyclerion Therapeutics, Inc. Deuterated sgc stimulators
US20230128032A1 (en) 2020-03-31 2023-04-27 Curtails Llc Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2022057836A1 (zh) * 2020-09-16 2022-03-24 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4240750A1 (en) 2020-11-04 2023-09-13 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
AR124297A1 (es) 2020-12-10 2023-03-15 Bayer Ag Ácidos pirazol piperidin carboxílicos sustituidos
CN116829545A (zh) 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸
JP7458683B2 (ja) 2020-12-10 2024-04-01 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのｓＧＣ活性化剤の使用
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CR20230532A (es) 2021-04-20 2024-03-22 Tisento Therapeutics Inc ESTIMULADORES DE GUANILIL CICLASA SOLUBLE (sGC)
US20240207265A1 (en) 2021-04-20 2024-06-27 Tisento Therapeutics Inc. TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
JP7607799B2 (ja) * 2021-04-27 2024-12-27 メッドシャイン ディスカバリー インコーポレイテッド ６員芳香族ヘテロ尿素環の誘導体及びその使用
WO2022265984A1 (en) 2021-06-14 2022-12-22 Curtails Llc Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
US20240342188A1 (en) 2021-08-11 2024-10-17 Curtails Llc Use of NEP Inhibitors for the Treatment of Laminitis
WO2023126436A1 (en) 2021-12-29 2023-07-06 Bayer Aktiengesellschaft Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound
US20250281480A1 (en) 2021-12-29 2025-09-11 Bayer Aktiengesellschaft Pharmaceutical dry powder inhalation formulation
IL313920A (en) 2021-12-29 2024-08-01 Bayer Ag Treatment of heart and lung disorders
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
CN115947689B (zh) * 2022-09-23 2025-08-29 湖南华腾制药有限公司 一种连续流微反应器合成利奥西呱中间体的方法
CN120225524A (zh) 2022-10-18 2025-06-27 帝善多制药公司 嘧啶sGC刺激剂
CN120112293A (zh) 2022-10-18 2025-06-06 帝善多制药公司 使用sGC刺激剂治疗线粒体疾病
AR133983A1 (es) 2023-09-28 2025-11-19 Bayer Ag Carboxamidas heterocíclicas sustituidas y su uso
CN117924280B (zh) * 2024-03-20 2024-07-12 中国人民解放军军事科学院军事医学研究院 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
ES2325045T3 (es) 1996-10-14 2009-08-24 Bayer Healthcare Ag Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DK1174431T3 (da) 1997-11-12 2012-08-20 Bayer Pharma AG 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE10057751A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
EP1339716B1 (de) 2000-11-22 2004-11-03 Bayer HealthCare AG lactam-substituierte pyrazolopyridinderivate
DE10122894A1 (de) * 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) * 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10350148B3 (de) 2003-10-28 2005-02-10 Daimlerchrysler Ag Baureihe für einen Fahrzeugsitz

Also Published As

Publication number Publication date
BRPI0309855B1 (pt) 2018-10-16
DE50303960D1 (de) 2006-08-03
BR0309855A (pt) 2005-03-01
CN1330649C (zh) 2007-08-08
EP1506193B1 (de) 2006-06-21
CY2014018I2 (el) 2015-12-09
EP1506193B3 (de) 2025-12-03
UY27793A1 (es) 2003-12-31
GT200300101A (es) 2004-03-08
LU92419I2 (fr) 2014-06-02
AU2003233061A1 (en) 2003-11-11
TW200404797A (en) 2004-04-01
ECSP045414A (es) 2005-01-03
NO329105B1 (no) 2010-08-23
DOP2003000639A (es) 2003-11-15
CN1665811A (zh) 2005-09-07
AU2003233061B2 (en) 2009-09-03
BE2014C030I2 (OSRAM) 2022-08-09
EP1506193A1 (de) 2005-02-16
FR14C0032I2 (fr) 2014-11-21
US7173037B2 (en) 2007-02-06
FR14C0032I1 (OSRAM) 2014-05-16
HRP20041166B1 (hr) 2013-05-31
ATE330957T1 (de) 2006-07-15
CY2014018I1 (el) 2015-12-09
PL214985B1 (pl) 2013-10-31
NO20045277L (no) 2004-12-01
KR101011864B1 (ko) 2011-02-01
UA78314C2 (uk) 2007-03-15
IL164958A (en) 2010-05-17
NO2014018I2 (no) 2015-08-31
HK1082247A1 (en) 2006-06-02
HRP20041166A2 (en) 2005-08-31
CA2485143C (en) 2011-04-19
RU2339638C2 (ru) 2008-11-27
WO2003095451A1 (de) 2003-11-20
DE10220570A1 (de) 2003-11-20
CA2485143A1 (en) 2003-11-20
PL373336A1 (pl) 2005-08-22
TWI282792B (en) 2007-06-21
KR20050003415A (ko) 2005-01-10
AR039789A1 (es) 2005-03-02
MXPA04011003A (es) 2005-02-14
PE20040197A1 (es) 2004-04-22
IL164958A0 (en) 2005-12-18
ES2268363T3 (es) 2007-03-16
CY1105579T1 (el) 2010-07-28
JP2005531553A (ja) 2005-10-20
BRPI0309855B8 (pt) 2021-05-25
DK1506193T3 (da) 2006-10-09
CU23453B7 (es) 2009-12-01
MY136841A (en) 2008-11-28
PT1506193E (pt) 2006-10-31
RU2339638C9 (ru) 2009-09-20
RU2004136277A (ru) 2005-06-27
US20060052397A1 (en) 2006-03-09
ZA200408925B (en) 2006-01-25
NO2014018I1 (no) 2014-07-18
SI1506193T1 (sl) 2006-12-31
NZ536417A (en) 2006-08-31
NL300659I2 (OSRAM) 2017-02-02

Similar Documents

Publication Publication Date Title
JP4455321B2 (ja) カルバメート置換ピラゾロピリジン類
JP4589720B2 (ja) ２−（１−ベンジル−１ｈ−ピラゾロ（３，４−ｂ）ピリジン−３−イル）−５−（４−ピリジニル）−４−ピリミジンアミン誘導体およびグアニル酸シクラーゼ刺激因子としてのそれらの使用
JP4246991B2 (ja) 新規なピリジン置換ピラゾロピリジン誘導体
JP4309653B2 (ja) 新規なスルホンアミド置換ピラゾロピリジン誘導体
JP2005501034A (ja) モルホリン架橋のピラゾロピリジン誘導体
JP2005537274A (ja) ４−アミノ置換ピリミジン誘導体
JP2006503854A (ja) 新規モルホリン架橋インダゾール誘導体
ZA200303887B (en) Novel pyridine-substituted pyrazolopyridine derivatives.
HK1082247B (en) Carbamate-substituted pyrazolopyridines

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090826

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20090826

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091023

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20091023

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20091105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100203

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4455321

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140212

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140212

Year of fee payment: 4

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140212

Year of fee payment: 4

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250